Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers

21 Feb 2019

Abstract excerpt

PURPOSE: We sought to examine the pharmacodynamic activation of the DNA damage response (DDR) pathway in tumors following anticancer treatment for confirmation of target engagement. EXPERIMENTAL DESIGN: We evaluated the time course and spatial activation of 3 protein biomarkers of DNA damage recognition and repair (γH2AX, pS343-Nbs1, and Rad51) simultaneously in a quantitative multiplex immunofluorescence assay...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30792217
DOI: 10.1158/1078-0432.ccr-18-2523

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage MarkersPMID 30792217Read ↗

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.Semantic proximity Read ↗

DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of RadiosensitivitySemantic proximity Read ↗

Leveraging a Patient-Derived Tumoroid Platform for Precision Radiotherapy: Uncovering DNA Damage Repair Inhibitor-Mediated Radiosensitization and Therapeutic Resistance in Rectal CancerSemantic proximity Read ↗

DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and SurvivalSemantic proximity Read ↗

Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry Enables Multiplex, Quantitative Pharmacodynamic Studies of Phospho-Signaling.Semantic proximity Read ↗

Validation of a flow cytometry‐based detection of γ‐H2AX, to measure DNA damage for clinical applicationsSemantic proximity Read ↗

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.Semantic proximity Read ↗

Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.Semantic proximity Read ↗

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal CancerSemantic proximity Read ↗

Complex engagement of DNA damage response pathways in human cancer and in lung tumor progressionSemantic proximity Read ↗

DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer TherapySemantic proximity Read ↗

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.